2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6078 Mutation-agnostic HBB gene replacement coupled to erythroid-selective expansion drives functional correction of β-hemoglobinopathies

Nowah Afangbedji, PhD, Hansen Tao2, Ishaan Vaswani, MS, BA3, Freja Kjellaug Amalia Ekman, BSc, MPhil4, Sridhar Selvaraj5, Ludwig Schmiderer6, Dick Nchang, BA7, Matthew Hebden Porteus, MD, PhD8
1 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
2 Stanford University, Stanford, California, United States
3 Stanford University, Stanford, California, United States
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States
6 Stanford University, Stanford, California, United States
7 Stanford University, Stanford, California, United States
8 Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States

Background:
β-Hemoglobinopathies are among the most common monogenic disorders worldwide. Although sickle cell disease results from a single pathogenic HBB variant, β-thalassemia encompasses >300 disease-causing HBB variants, creating a major challenge for mutation-specific gene-editing strategies. We developed a mutation-agnostic approach that replaces endogenous HBB with a functional β-globin cassette and couples gene correction to erythroid-selective expansion of edited progeny.

Methods:
Human CD34+ hematopoietic stem and progenitor cells (HSPCs) were engineered ex vivo using CRISPR-Cas9 and AAV6-mediated homology-directed repair (HDR). A hybrid β-globin cassette (HybHBB), comprising HBB exons 1–3 and heterologous γ-globin introns, was targeted to the endogenous HBB locus either alone or linked to a truncated erythropoietin receptor (tEPOR) designed to confer an erythroid-selective proliferative advantage. Editing efficiency, erythroid differentiation and expansion, p53 pathway activation, and colony-forming capacity were evaluated across multiple donors. Engineered HSPCs were transplanted into immunodeficient mice (n=5, N=25) to assess engraftment, multilineage hematopoiesis, and persistence of the therapeutic cassette. Translational activity was evaluated in patient-derived HSPCs representing three distinct β-thalassemia genotypes: IVS-II-654C>T, c.316-197C>T/c.-78A>G, and CD41-42/IVS-II-1G>A.

Results:
HybHBB-tEPOR conferred more than 2-fold erythroid expansion advantage compared with HybHBB alone and drove approximately 4-fold enrichment of HDR-edited alleles during erythroid differentiation, increasing edited allele frequencies from 20% after editing to as high as 80% in erythroid progeny. Robust enrichment was maintained at low AAV6 multiplicities of infection (MOI 300–650), conditions associated with reduced p53 stress-response activation. Both HybHBB and HybHBB-tEPOR rescued β-globin deficiency following endogenous HBB disruption, while edited HSPCs retained colony-forming capacity. At 17 weeks after transplantation, engineered HSPCs supported durable multilineage human hematopoiesis, with mean human CD45+ chimerism reaching up to 74.7% ± 4.8% in bone marrow, 45% ±11% in spleen, and 55.1 ±21.2% in peripheral blood. Importantly, across genetically distinct β-thalassemia patient-derived HSPCs, the platform restored adult hemoglobin production, increasing HbA from 6% to as high as 82% following erythroid differentiation.

Conclusions:
Mutation-agnostic HBB replacement coupled to erythroid-selective expansion converts moderate initial editing into a highly enriched population of functionally corrected erythroid cells while preserving HSPC progenitor function and in vivo engraftment. By achieving robust HbA restoration across genetically distinct β-thalassemia samples at low vector doses, HybHBB-tEPOR provides a potentially scalable, genotype-independent therapeutic strategy for both sickle cell disease and β-thalassemia.

Nowah Afangbedji, PhD: No relevant conflicts of interest to declare.